OSE Pharma’s Initial Public Offering couldn’t have been more successful as it just raised €21.1M. Noticing the strong demand for shares, the board of OSE Pharma has increased the price of the capital to €10.80 per share, corresponding to the top of the indicative price range of the offer. On this basis, the market capitalization of OSE Pharma stood at 108 million.

Two weeks ago, we presented you this French company, a rising star of cancer immunotherapy. After the success of its IPO, the group decided to fully exercise the extension clause covering a maximum of 293,250 new shares, or a maximum of nearly €3.2M.

Dominique Costantini

Dominique Costantini

We are very pleased with the success of our operation. We convinced French and European leading investors to join us in funding our clinical pivotal Phase III in lung cancer. The choice of a first exploratory Phase II study in partnership is now also possible (in therapeutic combination or with new indications against other cancers),” said Dominique Costantini, CEO of Pharma OSE.

Previous post

With €200 Million, Cellectis is on its way to make the Biggest French Biotech IPO ever

Next post

Strategic Partnership Between Green Cross and Nanolek

Let's Continue The Conversation

Feel free to send us comments about this article to comments@labiotech.eu and/or comment on that article on social media.